BIIB-105

N/A

Report date: 2024/09/21 20:00:09
NME

Base Information

Drug NameBIIB-105
Drug Alias NameION-541BIIB-105
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAtaxin-2 expression inhibitorsRNA interference
TargetsAtaxin-2
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals IncBiogen Inc
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A